Stocks and Investing
Stocks and Investing
Thu, May 5, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, May 4, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, May 3, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, May 2, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Hartaj Singh Upgraded (SRPT) to Buy on, May 2nd, 2016
Hartaj Singh of Oppenheimer, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, May 2nd, 2016.
Hartaj has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 2 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Yun Zhong of "Janney Montgomery Scott" Initiated at Hold on, Wednesday, April 20th, 2016
- Brian Abrahams of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $15 on, Tuesday, January 19th, 2016
This is the rating of the analyst that currently disagrees with Hartaj
- Mike Guo of "SunTrust Robinson Humphrey" Downgraded from Hold to Sell and Decreased Target to $4 on, Tuesday, April 26th, 2016
Contributing Sources